報價延遲最少15分鐘:2026/11/12 13:35 EST
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
4.025 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-0.75/-0.48
|
|
企業價值
393.96M
|
| 資產負債 |
|
每股賬面淨值
0.89
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Rezolute Inc is a late-stage rare disease company focused on developing therapies that treat refractory and debilitating hypoglycemia associated with various forms of hyperinsulinism. Its main clinical asset, Ersodetug, is a potential treatment for refractory hypoglycemia caused by multiple forms of hyperinsulinism. The company has a single reportable segment, which includes all of its activities as a clinical-stage biopharmaceutical company. |
